Compare AbbVie Inc (ABBV) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs CubeSmart — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while CubeSmart trades at $39.97 (market cap $9.26B). The key difference: AbbVie Inc is far larger — about 48.6× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.19%). Which is the better fit depends on your goals.
| ABBV | CUBE | |
|---|---|---|
Market Cap | $449.91B | $9.26B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $42.60 |
52-Week Low | $184.85 | $35.36 |
Enterprise Value | $513.38B | $12.75B |
Dividend Yield | 2.72% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
CubeSmart (CUBE) trades at $40.88, down 0.24% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.63, beating expectations, and maintains strong profitability with a 28.93% net income margin. Recent news highlights the upcoming Q2 2026 earnings release on July 30, 2026, and a declared dividend of $0.53 per share.
Outlook is balanced with a consensus price target of $43.17 suggesting modest upside, but risks include a high debt load and interest rate sensitivity. The stock offers a solid dividend yield, yet faces headwinds from macroeconomic uncertainty and competitive pressures in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
